問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Tri-Service General Hospital

List

803Cases

2015-06-01 - 2017-07-31

Phase II

Dose-response study of gevokizumab (S 78989) 3mg, 10 mg, 30 mg or 60 mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, placebo-controlled phase IIb study.

  • Condition/Disease

    diabetic kidney disease (DKD)

  • Test Drug

    S78989

Participate Sites
4Sites

Terminated4Sites

2014-10-01 - 2021-04-20

Phase III

Randomized, Double blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer — A Phase III trial

  • Condition/Disease

    FIGO stage IIIB cervical cancer

  • Test Drug

    Z-100

Participate Sites
17Sites

Terminated17Sites

2023-12-01 - 2024-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2014-11-15 - 2019-08-31

Phase II

A phase II study of PDC-1421 Capsule to evaluate the safety and efficacy in patients with major depressive disorder (MDD)

  • Condition/Disease

    major depressive disorder

  • Test Drug

    PDC-1421 Capsule

Participate Sites
4Sites

Terminated4Sites

2015-10-01 - 2015-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2017-09-01 - 2019-12-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2005-11-01 - 2008-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2015-01-01 - 2015-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2016-10-01 - 2017-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 45 46 47 48 49 81
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB